Identification

Name
Indoramin
Accession Number
DB08950
Type
Small Molecule
Groups
Withdrawn
Description

Indoramin is a discontinued piperidine antiadrenergic drug with the trade names Baratol and Doralese. It is a selective alpha-1 adrenergic antagonist with no reflex tachycardia and direct myocardial depression action.

Structure
Thumb
Synonyms
  • Indoramina
  • Indoramine
External IDs
Wy 21901
Product Ingredients
IngredientUNIICASInChI Key
Indoramin HydrochlorideDQ0Z3K8W9238821-52-2AFJSFHAKSSWOKG-UHFFFAOYSA-N
International/Other Brands
Baratol (Amdipharm) / Doralese (GlaxoSmithKline) / Doralese (Chemidex) / Vidora (Leurquin) / Wydora (Riemser)
Categories
UNII
0Z802HMY7H
CAS number
26844-12-2
Weight
Average: 347.4534
Monoisotopic: 347.199762437
Chemical Formula
C22H25N3O
InChI Key
JXZZEXZZKAWDSP-UHFFFAOYSA-N
InChI
InChI=1S/C22H25N3O/c26-22(17-6-2-1-3-7-17)24-19-11-14-25(15-12-19)13-10-18-16-23-21-9-5-4-8-20(18)21/h1-9,16,19,23H,10-15H2,(H,24,26)
IUPAC Name
N-{1-[2-(1H-indol-3-yl)ethyl]piperidin-4-yl}benzenecarboximidic acid
SMILES
OC(=NC1CCN(CCC2=CNC3=CC=CC=C23)CC1)C1=CC=CC=C1

Pharmacology

Indication
Not Available
Structured Indications
Not Available
Pharmacodynamics
Not Available
Mechanism of action
TargetActionsOrganism
UAlpha-1A adrenergic receptor
antagonist
Human
Absorption
Not Available
Volume of distribution
Not Available
Protein binding
Not Available
Metabolism
Not Available
Route of elimination
Not Available
Half life
Not Available
Clearance
Not Available
Toxicity
Not Available
Affected organisms
Not Available
Pathways
Not Available
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
DrugInteractionDrug group
7,8-Dichloro-1,2,3,4-tetrahydroisoquinoline7,8-Dichloro-1,2,3,4-tetrahydroisoquinoline may increase the hypotensive activities of Indoramin.Experimental
AcebutololAcebutolol may increase the orthostatic hypotensive activities of Indoramin.Approved
AdrafinilIndoramin may decrease the vasoconstricting activities of Adrafinil.Withdrawn
AldesleukinThe risk or severity of adverse effects can be increased when Indoramin is combined with Aldesleukin.Approved
AlfuzosinAlfuzosin may increase the hypotensive activities of Indoramin.Approved, Investigational
AliskirenIndoramin may increase the hypotensive activities of Aliskiren.Approved, Investigational
AlprenololAlprenolol may increase the orthostatic hypotensive activities of Indoramin.Approved, Withdrawn
AmbrisentanIndoramin may increase the hypotensive activities of Ambrisentan.Approved, Investigational
AmibegronIndoramin may decrease the vasoconstricting activities of Amibegron.Investigational
AmifostineIndoramin may increase the hypotensive activities of Amifostine.Approved, Investigational
AmilorideThe risk or severity of adverse effects can be increased when Indoramin is combined with Amiloride.Approved
AmiodaroneThe risk or severity of adverse effects can be increased when Amiodarone is combined with Indoramin.Approved, Investigational
AmitrazIndoramin may decrease the vasoconstricting activities of Amitraz.Vet Approved
AmlodipineIndoramin may increase the hypotensive activities of Amlodipine.Approved
AmobarbitalAmobarbital may increase the hypotensive activities of Indoramin.Approved, Illicit
Amphotericin BThe risk or severity of adverse effects can be increased when Amphotericin B is combined with Indoramin.Approved, Investigational
AmrinoneIndoramin may increase the hypotensive activities of Amrinone.Approved
Amyl NitriteThe risk or severity of adverse effects can be increased when Indoramin is combined with Amyl Nitrite.Approved
AnisodamineIndoramin may decrease the vasoconstricting activities of Anisodamine.Investigational
ApomorphineThe risk or severity of adverse effects can be increased when Apomorphine is combined with Indoramin.Approved, Investigational
ApraclonidineThe risk or severity of adverse effects can be increased when Indoramin is combined with Apraclonidine.Approved
ArbutamineIndoramin may decrease the vasoconstricting activities of Arbutamine.Approved
ArformoterolIndoramin may decrease the vasoconstricting activities of Arformoterol.Approved, Investigational
AripiprazoleAripiprazole may increase the hypotensive activities of Indoramin.Approved, Investigational
ArotinololArotinolol may increase the orthostatic hypotensive activities of Indoramin.Approved
Arsenic trioxideThe risk or severity of adverse effects can be increased when Arsenic trioxide is combined with Indoramin.Approved, Investigational
AtenololAtenolol may increase the orthostatic hypotensive activities of Indoramin.Approved
AzelnidipineIndoramin may increase the hypotensive activities of Azelnidipine.Approved
Azilsartan medoxomilThe risk or severity of adverse effects can be increased when Indoramin is combined with Azilsartan medoxomil.Approved
AzimilideIndoramin may increase the hypotensive activities of Azimilide.Investigational
BarbexacloneBarbexaclone may increase the hypotensive activities of Indoramin.Experimental
BarbitalBarbital may increase the hypotensive activities of Indoramin.Illicit
BarnidipineIndoramin may increase the hypotensive activities of Barnidipine.Approved
BefunololBefunolol may increase the orthostatic hypotensive activities of Indoramin.Experimental
BenazeprilIndoramin may increase the hypotensive activities of Benazepril.Approved, Investigational
BencyclaneIndoramin may increase the hypotensive activities of Bencyclane.Experimental
BendroflumethiazideIndoramin may increase the hypotensive activities of Bendroflumethiazide.Approved
BenidipineIndoramin may increase the hypotensive activities of Benidipine.Approved
BenmoxinBenmoxin may increase the hypotensive activities of Indoramin.Withdrawn
BepridilIndoramin may increase the hypotensive activities of Bepridil.Approved, Withdrawn
BetaxololBetaxolol may increase the orthostatic hypotensive activities of Indoramin.Approved
BethanidineBethanidine may increase the hypotensive activities of Indoramin.Approved
BevantololBevantolol may increase the orthostatic hypotensive activities of Indoramin.Approved
BietaserpineIndoramin may increase the hypotensive activities of Bietaserpine.Experimental
BimatoprostIndoramin may increase the hypotensive activities of Bimatoprost.Approved, Investigational
BisoprololBisoprolol may increase the orthostatic hypotensive activities of Indoramin.Approved
BitolterolIndoramin may decrease the vasoconstricting activities of Bitolterol.Withdrawn
BopindololBopindolol may increase the orthostatic hypotensive activities of Indoramin.Approved
BortezomibThe risk or severity of adverse effects can be increased when Bortezomib is combined with Indoramin.Approved, Investigational
BosentanBosentan may increase the hypotensive activities of Indoramin.Approved, Investigational
BQ-123Indoramin may increase the hypotensive activities of BQ-123.Investigational
BretyliumIndoramin may increase the hypotensive activities of Bretylium.Approved
BrimonidineBrimonidine may increase the antihypertensive activities of Indoramin.Approved
BrofaromineBrofaromine may increase the hypotensive activities of Indoramin.Experimental
BromocriptineThe risk or severity of adverse effects can be increased when Bromocriptine is combined with Indoramin.Approved, Investigational
BucindololBucindolol may increase the orthostatic hypotensive activities of Indoramin.Investigational
BufuralolBufuralol may increase the orthostatic hypotensive activities of Indoramin.Experimental, Investigational
BumetanideThe risk or severity of adverse effects can be increased when Indoramin is combined with Bumetanide.Approved
BunazosinIndoramin may increase the antihypertensive activities of Bunazosin.Investigational
BupivacaineThe risk or severity of adverse effects can be increased when Bupivacaine is combined with Indoramin.Approved, Investigational
BupranololBupranolol may increase the orthostatic hypotensive activities of Indoramin.Approved
CadralazineIndoramin may increase the hypotensive activities of Cadralazine.Experimental
CafedrineIndoramin may increase the hypotensive activities of Cafedrine.Investigational
CanagliflozinThe risk or severity of adverse effects can be increased when Indoramin is combined with Canagliflozin.Approved
CandesartanIndoramin may increase the hypotensive activities of Candesartan.Approved
CandoxatrilIndoramin may increase the hypotensive activities of Candoxatril.Experimental
CaptoprilIndoramin may increase the hypotensive activities of Captopril.Approved
CarbetocinThe risk or severity of adverse effects can be increased when Carbetocin is combined with Indoramin.Approved
CarboxyamidotriazoleIndoramin may increase the hypotensive activities of Carboxyamidotriazole.Investigational
CaroverineIndoramin may increase the hypotensive activities of Caroverine.Experimental
CaroxazoneCaroxazone may increase the hypotensive activities of Indoramin.Withdrawn
CarteololCarteolol may increase the orthostatic hypotensive activities of Indoramin.Approved
CarvedilolCarvedilol may increase the orthostatic hypotensive activities of Indoramin.Approved, Investigational
CeliprololCeliprolol may increase the orthostatic hypotensive activities of Indoramin.Approved, Investigational
ChlorothiazideIndoramin may increase the hypotensive activities of Chlorothiazide.Approved, Vet Approved
ChlorpromazineThe risk or severity of adverse effects can be increased when Chlorpromazine is combined with Indoramin.Approved, Vet Approved
ChlorthalidoneIndoramin may increase the hypotensive activities of Chlorthalidone.Approved
CicletanineIndoramin may increase the hypotensive activities of Cicletanine.Investigational
CilazaprilIndoramin may increase the hypotensive activities of Cilazapril.Approved
CilnidipineIndoramin may increase the hypotensive activities of Cilnidipine.Approved
CinnarizineIndoramin may increase the hypotensive activities of Cinnarizine.Approved
CirazolineIndoramin may decrease the vasoconstricting activities of Cirazoline.Experimental
ClenbuterolIndoramin may decrease the vasoconstricting activities of Clenbuterol.Approved, Vet Approved
ClevidipineIndoramin may increase the hypotensive activities of Clevidipine.Approved
ClofarabineThe risk or severity of adverse effects can be increased when Clofarabine is combined with Indoramin.Approved, Investigational
ClomipramineThe risk or severity of adverse effects can be increased when Clomipramine is combined with Indoramin.Approved, Vet Approved
ClonidineClonidine may increase the hypotensive activities of Indoramin.Approved
CloranololCloranolol may increase the orthostatic hypotensive activities of Indoramin.Experimental
ClozapineThe risk or severity of adverse effects can be increased when Clozapine is combined with Indoramin.Approved
ConivaptanThe risk or severity of adverse effects can be increased when Conivaptan is combined with Indoramin.Approved, Investigational
CryptenamineIndoramin may increase the hypotensive activities of Cryptenamine.Approved
CyclopenthiazideIndoramin may increase the hypotensive activities of Cyclopenthiazide.Experimental
CyclothiazideIndoramin may increase the hypotensive activities of Cyclothiazide.Approved
DapagliflozinThe risk or severity of adverse effects can be increased when Indoramin is combined with Dapagliflozin.Approved
DapoxetineDapoxetine may increase the orthostatic hypotensive activities of Indoramin.Investigational
DarodipineIndoramin may increase the hypotensive activities of Darodipine.Experimental
DebrisoquinDebrisoquin may increase the hypotensive activities of Indoramin.Approved
DelaprilIndoramin may increase the hypotensive activities of Delapril.Experimental
DeserpidineIndoramin may increase the hypotensive activities of Deserpidine.Approved
DesfluraneThe risk or severity of adverse effects can be increased when Desflurane is combined with Indoramin.Approved
DetomidineIndoramin may decrease the vasoconstricting activities of Detomidine.Vet Approved
DexmedetomidineThe risk or severity of adverse effects can be increased when Indoramin is combined with Dexmedetomidine.Approved, Vet Approved
DiazoxideDiazoxide may increase the hypotensive activities of Indoramin.Approved
DiclofenamideThe risk or severity of adverse effects can be increased when Indoramin is combined with Diclofenamide.Approved
diethylnorspermineIndoramin may increase the hypotensive activities of diethylnorspermine.Investigational
DihydralazineIndoramin may increase the hypotensive activities of Dihydralazine.Investigational
DiltiazemIndoramin may increase the hypotensive activities of Diltiazem.Approved
DinutuximabThe risk or severity of adverse effects can be increased when Indoramin is combined with Dinutuximab.Approved
DipivefrinIndoramin may decrease the vasoconstricting activities of Dipivefrin.Approved
DipyridamoleThe risk or severity of adverse effects can be increased when Indoramin is combined with Dipyridamole.Approved
DobutamineIndoramin may decrease the vasoconstricting activities of Dobutamine.Approved
DopexamineIndoramin may decrease the vasoconstricting activities of Dopexamine.Investigational
DorzolamideIndoramin may increase the hypotensive activities of Dorzolamide.Approved
DotarizineIndoramin may increase the hypotensive activities of Dotarizine.Investigational
DoxazosinThe risk or severity of adverse effects can be increased when Indoramin is combined with Doxazosin.Approved
DroxidopaIndoramin may decrease the vasoconstricting activities of Droxidopa.Approved, Investigational
DuloxetineIndoramin may increase the orthostatic hypotensive activities of Duloxetine.Approved
EfonidipineIndoramin may increase the hypotensive activities of Efonidipine.Approved
EmpagliflozinThe risk or severity of adverse effects can be increased when Indoramin is combined with Empagliflozin.Approved
EnalaprilIndoramin may increase the hypotensive activities of Enalapril.Approved, Vet Approved
EnalaprilatIndoramin may increase the hypotensive activities of Enalaprilat.Approved
EndralazineIndoramin may increase the hypotensive activities of Endralazine.Experimental
EpanololEpanolol may increase the orthostatic hypotensive activities of Indoramin.Experimental
EperisoneIndoramin may increase the hypotensive activities of Eperisone.Approved, Investigational
EphedrineIndoramin may decrease the vasoconstricting activities of Ephedrine.Approved
EpinephrineIndoramin may decrease the vasoconstricting activities of Epinephrine.Approved, Vet Approved
EplerenoneThe risk or severity of adverse effects can be increased when Indoramin is combined with Eplerenone.Approved
EpoprostenolIndoramin may increase the hypotensive activities of Epoprostenol.Approved
EprosartanIndoramin may increase the hypotensive activities of Eprosartan.Approved
ErgotamineIndoramin may decrease the vasoconstricting activities of Ergotamine.Approved
EsmololEsmolol may increase the orthostatic hypotensive activities of Indoramin.Approved
Etacrynic acidThe risk or severity of adverse effects can be increased when Indoramin is combined with Etacrynic acid.Approved
EtilefrineIndoramin may decrease the vasoconstricting activities of Etilefrine.Withdrawn
FelodipineIndoramin may increase the hypotensive activities of Felodipine.Approved, Investigational
FendilineIndoramin may increase the hypotensive activities of Fendiline.Withdrawn
FenoldopamIndoramin may increase the hypotensive activities of Fenoldopam.Approved
FenoterolIndoramin may decrease the vasoconstricting activities of Fenoterol.Approved
Ferulic acidIndoramin may increase the hypotensive activities of Ferulic acid.Experimental
FimasartanThe risk or severity of adverse effects can be increased when Fimasartan is combined with Indoramin.Approved
FlunarizineIndoramin may increase the hypotensive activities of Flunarizine.Approved
FormoterolIndoramin may decrease the vasoconstricting activities of Formoterol.Approved, Investigational
FosinoprilIndoramin may increase the hypotensive activities of Fosinopril.Approved
FurazolidoneFurazolidone may increase the hypotensive activities of Indoramin.Approved, Vet Approved
FurosemideThe risk or severity of adverse effects can be increased when Indoramin is combined with Furosemide.Approved, Vet Approved
GabapentinIndoramin may increase the hypotensive activities of Gabapentin.Approved, Investigational
GallopamilIndoramin may increase the hypotensive activities of Gallopamil.Investigational
GuanabenzIndoramin may increase the hypotensive activities of Guanabenz.Approved
GuanadrelIndoramin may increase the hypotensive activities of Guanadrel.Approved
GuanazodineIndoramin may increase the hypotensive activities of Guanazodine.Experimental
GuanethidineGuanethidine may increase the hypotensive activities of Indoramin.Approved
GuanfacineGuanfacine may increase the hypotensive activities of Indoramin.Approved, Investigational
GuanoclorIndoramin may increase the hypotensive activities of Guanoclor.Experimental
GuanoxabenzIndoramin may increase the hypotensive activities of Guanoxabenz.Experimental
GuanoxanIndoramin may increase the hypotensive activities of Guanoxan.Experimental
HalothaneThe risk or severity of adverse effects can be increased when Halothane is combined with Indoramin.Approved, Vet Approved
HarmalineHarmaline may increase the hypotensive activities of Indoramin.Experimental
HexamethoniumIndoramin may increase the hypotensive activities of Hexamethonium.Experimental
HexobarbitalHexobarbital may increase the hypotensive activities of Indoramin.Approved
HexoprenalineIndoramin may decrease the vasoconstricting activities of Hexoprenaline.Approved, Withdrawn
HigenamineIndoramin may decrease the vasoconstricting activities of Higenamine.Investigational
HydracarbazineHydracarbazine may increase the hypotensive activities of Indoramin.Experimental
HydralazineHydralazine may increase the hypotensive activities of Indoramin.Approved
HydrochlorothiazideIndoramin may increase the hypotensive activities of Hydrochlorothiazide.Approved, Vet Approved
HydroflumethiazideIndoramin may increase the hypotensive activities of Hydroflumethiazide.Approved
IloprostIloprost may increase the hypotensive activities of Indoramin.Approved, Investigational
ImidaprilThe risk or severity of adverse effects can be increased when Imidapril is combined with Indoramin.Investigational
ImipramineThe risk or severity of adverse effects can be increased when Imipramine is combined with Indoramin.Approved
IndapamideIndoramin may increase the hypotensive activities of Indapamide.Approved
IndenololIndenolol may increase the orthostatic hypotensive activities of Indoramin.Withdrawn
IproclozideIproclozide may increase the hypotensive activities of Indoramin.Withdrawn
IproniazidIproniazid may increase the hypotensive activities of Indoramin.Withdrawn
IrbesartanIndoramin may increase the hypotensive activities of Irbesartan.Approved, Investigational
IsocarboxazidIsocarboxazid may increase the hypotensive activities of Indoramin.Approved
IsoetarineIndoramin may decrease the vasoconstricting activities of Isoetarine.Approved
IsofluraneThe risk or severity of adverse effects can be increased when Indoramin is combined with Isoflurane.Approved, Vet Approved
IsoprenalineIndoramin may decrease the vasoconstricting activities of Isoprenaline.Approved
Isosorbide DinitrateThe risk or severity of adverse effects can be increased when Indoramin is combined with Isosorbide Dinitrate.Approved
Isosorbide MononitrateThe risk or severity of adverse effects can be increased when Indoramin is combined with Isosorbide Mononitrate.Approved
IsoxsuprineThe risk or severity of adverse effects can be increased when Indoramin is combined with Isoxsuprine.Approved, Withdrawn
IsradipineIndoramin may increase the hypotensive activities of Isradipine.Approved
KetanserinIndoramin may increase the hypotensive activities of Ketanserin.Investigational
LabetalolLabetalol may increase the orthostatic hypotensive activities of Indoramin.Approved
LacidipineIndoramin may increase the hypotensive activities of Lacidipine.Approved
LamotrigineIndoramin may increase the hypotensive activities of Lamotrigine.Approved, Investigational
LandiololLandiolol may increase the orthostatic hypotensive activities of Indoramin.Investigational
LatanoprostIndoramin may increase the hypotensive activities of Latanoprost.Approved, Investigational
LercanidipineIndoramin may increase the hypotensive activities of Lercanidipine.Approved, Investigational
LevobunololThe risk or severity of adverse effects can be increased when Indoramin is combined with Levobunolol.Approved
LevobupivacaineThe risk or severity of adverse effects can be increased when Indoramin is combined with Levobupivacaine.Approved
LevodopaIndoramin may increase the orthostatic hypotensive activities of Levodopa.Approved
LevosimendanThe risk or severity of adverse effects can be increased when Indoramin is combined with Levosimendan.Approved, Investigational
LidoflazineIndoramin may increase the hypotensive activities of Lidoflazine.Experimental
LinsidomineIndoramin may increase the hypotensive activities of Linsidomine.Experimental
LisinoprilIndoramin may increase the hypotensive activities of Lisinopril.Approved, Investigational
LofexidineIndoramin may increase the hypotensive activities of Lofexidine.Approved, Investigational
LosartanIndoramin may increase the hypotensive activities of Losartan.Approved
MacitentanIndoramin may increase the hypotensive activities of Macitentan.Approved
Magnesium SulfateIndoramin may increase the hypotensive activities of Magnesium Sulfate.Approved, Vet Approved
ManidipineIndoramin may increase the hypotensive activities of Manidipine.Approved
MannitolThe risk or severity of adverse effects can be increased when Indoramin is combined with Mannitol.Approved, Investigational
MebanazineMebanazine may increase the hypotensive activities of Indoramin.Withdrawn
MecamylamineMecamylamine may increase the hypotensive activities of Indoramin.Approved
MedetomidineIndoramin may decrease the vasoconstricting activities of Medetomidine.Vet Approved
MephentermineIndoramin may decrease the vasoconstricting activities of Mephentermine.Approved
MepindololMepindolol may increase the orthostatic hypotensive activities of Indoramin.Experimental
MetaraminolIndoramin may decrease the vasoconstricting activities of Metaraminol.Approved, Investigational
MethazolamideThe risk or severity of adverse effects can be increased when Indoramin is combined with Methazolamide.Approved
MethohexitalMethohexital may increase the hypotensive activities of Indoramin.Approved
MethoserpidineIndoramin may increase the hypotensive activities of Methoserpidine.Experimental
MethoxamineIndoramin may decrease the vasoconstricting activities of Methoxamine.Approved
MethoxyphenamineIndoramin may decrease the vasoconstricting activities of Methoxyphenamine.Experimental
MethyclothiazideThe risk or severity of adverse effects can be increased when Indoramin is combined with Methyclothiazide.Approved
MethyldopaIndoramin may increase the hypotensive activities of Methyldopa.Approved
Methylene blueMethylene blue may increase the hypotensive activities of Indoramin.Investigational
MethylphenidateMethylphenidate may decrease the antihypertensive activities of Indoramin.Approved, Investigational
MethylphenobarbitalMethylphenobarbital may increase the hypotensive activities of Indoramin.Approved
MetipranololIndoramin may increase the hypotensive activities of Metipranolol.Approved
MetolazoneIndoramin may increase the hypotensive activities of Metolazone.Approved
MetoprololMetoprolol may increase the orthostatic hypotensive activities of Indoramin.Approved, Investigational
MetyrosineIndoramin may increase the hypotensive activities of Metyrosine.Approved
MibefradilIndoramin may increase the hypotensive activities of Mibefradil.Withdrawn
MidodrineIndoramin may decrease the vasoconstricting activities of Midodrine.Approved
MinaprineMinaprine may increase the hypotensive activities of Indoramin.Approved
MinoxidilMinoxidil may increase the hypotensive activities of Indoramin.Approved
MirabegronIndoramin may decrease the vasoconstricting activities of Mirabegron.Approved
MirodenafilMirodenafil may increase the hypotensive activities of Indoramin.Investigational
MoclobemideMoclobemide may increase the hypotensive activities of Indoramin.Approved
MoexiprilIndoramin may increase the hypotensive activities of Moexipril.Approved
MolsidomineMolsidomine may increase the hypotensive activities of Indoramin.Approved
MorphineThe risk or severity of adverse effects can be increased when Indoramin is combined with Morphine.Approved, Investigational
MoxonidineIndoramin may increase the hypotensive activities of Moxonidine.Approved
MuzolimineIndoramin may increase the hypotensive activities of Muzolimine.Experimental
NabiloneThe risk or severity of adverse effects can be increased when Indoramin is combined with Nabilone.Approved, Investigational
NadololNadolol may increase the orthostatic hypotensive activities of Indoramin.Approved
NaftopidilIndoramin may increase the hypotensive activities of Naftopidil.Investigational
NaphazolineIndoramin may decrease the vasoconstricting activities of Naphazoline.Approved
NebivololIndoramin may increase the hypotensive activities of Nebivolol.Approved, Investigational
NesiritideThe risk or severity of adverse effects can be increased when Indoramin is combined with Nesiritide.Approved, Investigational
NialamideNialamide may increase the hypotensive activities of Indoramin.Withdrawn
NicardipineIndoramin may increase the hypotensive activities of Nicardipine.Approved
NicorandilNicorandil may increase the hypotensive activities of Indoramin.Approved
NifedipineIndoramin may increase the hypotensive activities of Nifedipine.Approved
NiguldipineIndoramin may increase the hypotensive activities of Niguldipine.Experimental
NiludipineIndoramin may increase the hypotensive activities of Niludipine.Experimental
NilvadipineIndoramin may increase the hypotensive activities of Nilvadipine.Approved
NimesulideIndoramin may increase the hypotensive activities of Nimesulide.Approved, Withdrawn
NimodipineIndoramin may increase the hypotensive activities of Nimodipine.Approved
NisoldipineIndoramin may increase the hypotensive activities of Nisoldipine.Approved
NitrendipineIndoramin may increase the hypotensive activities of Nitrendipine.Approved
Nitric OxideThe risk or severity of adverse effects can be increased when Indoramin is combined with Nitric Oxide.Approved
NitroglycerinThe risk or severity of adverse effects can be increased when Indoramin is combined with Nitroglycerin.Approved, Investigational
NitroprussideNitroprusside may increase the hypotensive activities of Indoramin.Approved
NorepinephrineIndoramin may decrease the vasoconstricting activities of Norepinephrine.Approved
NorfenefrineIndoramin may decrease the vasoconstricting activities of Norfenefrine.Experimental
NylidrinIndoramin may decrease the vasoconstricting activities of Nylidrin.Approved
ObinutuzumabIndoramin may increase the hypotensive activities of Obinutuzumab.Approved
OctamoxinOctamoxin may increase the hypotensive activities of Indoramin.Withdrawn
OctopamineIndoramin may decrease the vasoconstricting activities of Octopamine.Experimental
OlmesartanIndoramin may increase the hypotensive activities of Olmesartan.Approved, Investigational
OlodaterolIndoramin may decrease the vasoconstricting activities of Olodaterol.Approved
OmapatrilatIndoramin may increase the hypotensive activities of Omapatrilat.Investigational
OrciprenalineIndoramin may decrease the vasoconstricting activities of Orciprenaline.Approved
OtiloniumIndoramin may increase the hypotensive activities of Otilonium.Experimental
OxprenololOxprenolol may increase the orthostatic hypotensive activities of Indoramin.Approved
OxyfedrineIndoramin may decrease the vasoconstricting activities of Oxyfedrine.Experimental
OxymetazolineIndoramin may decrease the vasoconstricting activities of Oxymetazoline.Approved
PaclitaxelThe risk or severity of adverse effects can be increased when Indoramin is combined with Paclitaxel.Approved, Vet Approved
PapaverineThe risk or severity of adverse effects can be increased when Indoramin is combined with Papaverine.Approved
PargylinePargyline may increase the hypotensive activities of Indoramin.Approved
PenbutololPenbutolol may increase the orthostatic hypotensive activities of Indoramin.Approved, Investigational
PentobarbitalPentobarbital may increase the hypotensive activities of Indoramin.Approved, Vet Approved
PentoliniumIndoramin may increase the hypotensive activities of Pentolinium.Approved
PentoxifyllinePentoxifylline may increase the hypotensive activities of Indoramin.Approved, Investigational
PerhexilineIndoramin may increase the hypotensive activities of Perhexiline.Approved
PerindoprilIndoramin may increase the hypotensive activities of Perindopril.Approved
PhenelzinePhenelzine may increase the hypotensive activities of Indoramin.Approved
PheniprazinePheniprazine may increase the hypotensive activities of Indoramin.Withdrawn
PhenobarbitalPhenobarbital may increase the hypotensive activities of Indoramin.Approved
PhenoxybenzamineIndoramin may increase the hypotensive activities of Phenoxybenzamine.Approved
PhenoxypropazinePhenoxypropazine may increase the hypotensive activities of Indoramin.Withdrawn
PhentolamineIndoramin may increase the hypotensive activities of Phentolamine.Approved
PhenylephrineIndoramin may decrease the vasoconstricting activities of Phenylephrine.Approved
PhenylpropanolamineIndoramin may decrease the vasoconstricting activities of Phenylpropanolamine.Approved, Vet Approved, Withdrawn
PinacidilPinacidil may increase the hypotensive activities of Indoramin.Withdrawn
PinaveriumIndoramin may increase the hypotensive activities of Pinaverium.Approved
PindololPindolol may increase the orthostatic hypotensive activities of Indoramin.Approved
PipamperoneThe risk or severity of adverse effects can be increased when Indoramin is combined with Pipamperone.Approved
PirbuterolIndoramin may decrease the vasoconstricting activities of Pirbuterol.Approved
PirlindolePirlindole may increase the hypotensive activities of Indoramin.Approved
PivhydrazinePivhydrazine may increase the hypotensive activities of Indoramin.Withdrawn
PolythiazideIndoramin may increase the hypotensive activities of Polythiazide.Approved
PractololPractolol may increase the orthostatic hypotensive activities of Indoramin.Approved
PramipexoleThe risk or severity of adverse effects can be increased when Indoramin is combined with Pramipexole.Approved, Investigational
PrazosinThe risk or severity of adverse effects can be increased when Indoramin is combined with Prazosin.Approved
PregabalinIndoramin may increase the hypotensive activities of Pregabalin.Approved, Illicit, Investigational
PrenalterolIndoramin may decrease the vasoconstricting activities of Prenalterol.Experimental
PrenylamineIndoramin may increase the hypotensive activities of Prenylamine.Withdrawn
PrimidonePrimidone may increase the hypotensive activities of Indoramin.Approved, Vet Approved
ProcaterolIndoramin may decrease the vasoconstricting activities of Procaterol.Approved
PropofolThe risk or severity of adverse effects can be increased when Indoramin is combined with Propofol.Approved, Investigational, Vet Approved
PropranololPropranolol may increase the orthostatic hypotensive activities of Indoramin.Approved, Investigational
PseudoephedrineIndoramin may decrease the vasoconstricting activities of Pseudoephedrine.Approved
QuetiapineThe risk or severity of adverse effects can be increased when Indoramin is combined with Quetiapine.Approved
QuinaprilIndoramin may increase the hypotensive activities of Quinapril.Approved, Investigational
QuinineQuinine may increase the hypotensive activities of Indoramin.Approved
RacepinephrineIndoramin may decrease the vasoconstricting activities of Racepinephrine.Approved
RactopamineIndoramin may decrease the vasoconstricting activities of Ractopamine.Vet Approved
RamiprilIndoramin may increase the hypotensive activities of Ramipril.Approved
RasagilineRasagiline may increase the hypotensive activities of Indoramin.Approved
RemifentanilThe risk or severity of adverse effects can be increased when Indoramin is combined with Remifentanil.Approved
RemikirenIndoramin may increase the hypotensive activities of Remikiren.Approved
ReproterolIndoramin may decrease the vasoconstricting activities of Reproterol.Investigational
RescinnamineIndoramin may increase the hypotensive activities of Rescinnamine.Approved
ReserpineReserpine may increase the hypotensive activities of Indoramin.Approved
RilmenidineIndoramin may increase the hypotensive activities of Rilmenidine.Investigational
RimiterolIndoramin may decrease the vasoconstricting activities of Rimiterol.Experimental
RiociguatIndoramin may increase the hypotensive activities of Riociguat.Approved
RisedronateIndoramin may increase the hypotensive activities of Risedronate.Approved, Investigational
RisperidoneIndoramin may increase the hypotensive activities of Risperidone.Approved, Investigational
RitobegronIndoramin may decrease the vasoconstricting activities of Ritobegron.Investigational
RitodrineIndoramin may decrease the vasoconstricting activities of Ritodrine.Approved
RituximabIndoramin may increase the hypotensive activities of Rituximab.Approved
RomifidineIndoramin may decrease the vasoconstricting activities of Romifidine.Vet Approved
RopiniroleThe risk or severity of adverse effects can be increased when Indoramin is combined with Ropinirole.Approved, Investigational
RopivacaineThe risk or severity of adverse effects can be increased when Indoramin is combined with Ropivacaine.Approved
RotigotineThe risk or severity of adverse effects can be increased when Indoramin is combined with Rotigotine.Approved
SacubitrilThe risk or severity of adverse effects can be increased when Indoramin is combined with Sacubitril.Approved
SafrazineSafrazine may increase the hypotensive activities of Indoramin.Withdrawn
SalbutamolIndoramin may decrease the vasoconstricting activities of Salbutamol.Approved, Vet Approved
SalmeterolIndoramin may decrease the vasoconstricting activities of Salmeterol.Approved
SaprisartanIndoramin may increase the hypotensive activities of Saprisartan.Experimental
SecobarbitalSecobarbital may increase the hypotensive activities of Indoramin.Approved, Vet Approved
SelegilineSelegiline may increase the hypotensive activities of Indoramin.Approved, Investigational, Vet Approved
SelexipagIndoramin may increase the hypotensive activities of Selexipag.Approved
SevofluraneThe risk or severity of adverse effects can be increased when Indoramin is combined with Sevoflurane.Approved, Vet Approved
SildenafilSildenafil may increase the hypotensive activities of Indoramin.Approved, Investigational
SilodosinSilodosin may increase the antihypertensive activities of Indoramin.Approved
SitaxentanIndoramin may increase the hypotensive activities of Sitaxentan.Approved, Investigational, Withdrawn
Sodium NitriteThe risk or severity of adverse effects can be increased when Indoramin is combined with Sodium Nitrite.Approved
SolabegronIndoramin may decrease the vasoconstricting activities of Solabegron.Investigational
SotalolSotalol may increase the orthostatic hypotensive activities of Indoramin.Approved
SpiraprilIndoramin may increase the hypotensive activities of Spirapril.Approved
SpironolactoneThe risk or severity of adverse effects can be increased when Indoramin is combined with Spironolactone.Approved
StreptokinaseThe risk or severity of adverse effects can be increased when Indoramin is combined with Streptokinase.Approved
SufentanilThe risk or severity of adverse effects can be increased when Indoramin is combined with Sufentanil.Approved, Investigational
SulpirideThe risk or severity of adverse effects can be increased when Indoramin is combined with Sulpiride.Approved
SynephrineIndoramin may decrease the vasoconstricting activities of Synephrine.Experimental
TadalafilTadalafil may increase the hypotensive activities of Indoramin.Approved, Investigational
TalinololTalinolol may increase the orthostatic hypotensive activities of Indoramin.Investigational
TamsulosinThe risk or severity of adverse effects can be increased when Indoramin is combined with Tamsulosin.Approved, Investigational
TelmisartanIndoramin may increase the hypotensive activities of Telmisartan.Approved, Investigational
TemocaprilIndoramin may increase the hypotensive activities of Temocapril.Experimental, Investigational
TerazosinThe risk or severity of adverse effects can be increased when Indoramin is combined with Terazosin.Approved
TerbutalineIndoramin may decrease the vasoconstricting activities of Terbutaline.Approved
TerlipressinIndoramin may increase the hypotensive activities of Terlipressin.Approved, Investigational
TerodilineIndoramin may increase the hypotensive activities of Terodiline.Experimental
TertatololTertatolol may increase the orthostatic hypotensive activities of Indoramin.Experimental
TetrahydropalmatineIndoramin may increase the hypotensive activities of Tetrahydropalmatine.Investigational
ThalidomideThe risk or severity of adverse effects can be increased when Indoramin is combined with Thalidomide.Approved, Investigational, Withdrawn
TheodrenalineIndoramin may increase the hypotensive activities of Theodrenaline.Investigational
ThiamylalThiamylal may increase the hypotensive activities of Indoramin.Approved, Vet Approved
ThiopentalThiopental may increase the hypotensive activities of Indoramin.Approved, Vet Approved
ThioridazineThe risk or severity of adverse effects can be increased when Indoramin is combined with Thioridazine.Withdrawn
TiboloneIndoramin may increase the hypotensive activities of Tibolone.Approved
TicrynafenIndoramin may increase the hypotensive activities of Ticrynafen.Withdrawn
TimololTimolol may increase the orthostatic hypotensive activities of Indoramin.Approved
TizanidineThe risk or severity of adverse effects can be increased when Indoramin is combined with Tizanidine.Approved
TolazolineIndoramin may increase the hypotensive activities of Tolazoline.Approved, Vet Approved
TolcaponeThe risk or severity of adverse effects can be increased when Indoramin is combined with Tolcapone.Approved, Withdrawn
Tolfenamic AcidIndoramin may increase the hypotensive activities of Tolfenamic Acid.Approved
TolonidineIndoramin may increase the hypotensive activities of Tolonidine.Experimental
ToloxatoneToloxatone may increase the hypotensive activities of Indoramin.Approved
TorasemideIndoramin may increase the hypotensive activities of Torasemide.Approved
TrandolaprilIndoramin may increase the hypotensive activities of Trandolapril.Approved
TranilastIndoramin may increase the hypotensive activities of Tranilast.Approved, Investigational
Trans-2-PhenylcyclopropylamineTrans-2-Phenylcyclopropylamine may increase the hypotensive activities of Indoramin.Experimental
TranylcypromineTranylcypromine may increase the hypotensive activities of Indoramin.Approved
TravoprostIndoramin may increase the hypotensive activities of Travoprost.Approved
TreprostinilIndoramin may increase the hypotensive activities of Treprostinil.Approved, Investigational
TretinoinThe risk or severity of adverse effects can be increased when Indoramin is combined with Tretinoin.Approved, Investigational, Nutraceutical
TretoquinolIndoramin may decrease the vasoconstricting activities of Tretoquinol.Experimental
TriamtereneThe risk or severity of adverse effects can be increased when Indoramin is combined with Triamterene.Approved
TrichlormethiazideIndoramin may increase the hypotensive activities of Trichlormethiazide.Approved, Vet Approved
TrimazosinIndoramin may increase the hypotensive activities of Trimazosin.Experimental
TrimethaphanTrimethaphan may increase the hypotensive activities of Indoramin.Approved
TulobuterolIndoramin may decrease the vasoconstricting activities of Tulobuterol.Investigational
UdenafilUdenafil may increase the hypotensive activities of Indoramin.Approved, Investigational
UnoprostoneIndoramin may increase the hypotensive activities of Unoprostone.Approved
UrapidilIndoramin may increase the hypotensive activities of Urapidil.Investigational
ValsartanIndoramin may increase the hypotensive activities of Valsartan.Approved, Investigational
VardenafilVardenafil may increase the hypotensive activities of Indoramin.Approved
VerapamilIndoramin may increase the hypotensive activities of Verapamil.Approved
VincamineIndoramin may increase the hypotensive activities of Vincamine.Experimental
VinpocetineIndoramin may increase the hypotensive activities of Vinpocetine.Investigational
XamoterolIndoramin may decrease the vasoconstricting activities of Xamoterol.Experimental
XipamideIndoramin may increase the hypotensive activities of Xipamide.Experimental
XylazineIndoramin may decrease the vasoconstricting activities of Xylazine.Vet Approved
XylometazolineIndoramin may increase the hypotensive activities of Xylometazoline.Approved
YM-178Indoramin may decrease the vasoconstricting activities of YM-178.Investigational
YohimbineYohimbine may decrease the antihypertensive activities of Indoramin.Approved, Vet Approved
ZiconotideIndoramin may increase the hypotensive activities of Ziconotide.Approved
ZofenoprilIndoramin may increase the hypotensive activities of Zofenopril.Experimental
Food Interactions
Not Available

References

Synthesis Reference

U.S. Patent 3,527,761

General References
Not Available
External Links
KEGG Drug
D04531
PubChem Compound
33625
PubChem Substance
310264915
ChemSpider
31014
BindingDB
50033113
ChEBI
135470
ChEMBL
CHEMBL279516
Drugs.com
Drugs.com Drug Page
Wikipedia
Indoramin
ATC Codes
C02CA02 — Indoramin
AHFS Codes
Not Available
PDB Entries
Not Available
FDA label
Not Available
MSDS
Download (17.2 KB)

Clinical Trials

Clinical Trials
Not Available

Pharmacoeconomics

Manufacturers
Not Available
Packagers
Not Available
Dosage forms
Not Available
Prices
Not Available
Patents
Not Available

Properties

State
Solid
Experimental Properties
PropertyValueSource
melting point (°C)208-210U.S. Patent 3,527,761
Predicted Properties
PropertyValueSource
Water Solubility0.00498 mg/mLALOGPS
logP4.02ALOGPS
logP3.02ChemAxon
logS-4.8ALOGPS
pKa (Strongest Acidic)8.47ChemAxon
pKa (Strongest Basic)9.59ChemAxon
Physiological Charge2ChemAxon
Hydrogen Acceptor Count3ChemAxon
Hydrogen Donor Count2ChemAxon
Polar Surface Area51.62 Å2ChemAxon
Rotatable Bond Count5ChemAxon
Refractivity106.46 m3·mol-1ChemAxon
Polarizability40.94 Å3ChemAxon
Number of Rings4ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleNoChemAxon
MDDR-like RuleNoChemAxon
Predicted ADMET features
Not Available

Spectra

Mass Spec (NIST)
Not Available
Spectra
SpectrumSpectrum TypeSplash Key
Predicted MS/MS Spectrum - 10V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 10V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Negative (Annotated)Predicted LC-MS/MSNot Available

Taxonomy

Description
This compound belongs to the class of organic compounds known as tryptamines and derivatives. These are compounds containing the tryptamine backbone, which is structurally characterized by an indole ring substituted at the 3-position by an ethanamine.
Kingdom
Organic compounds
Super Class
Organoheterocyclic compounds
Class
Indoles and derivatives
Sub Class
Tryptamines and derivatives
Direct Parent
Tryptamines and derivatives
Alternative Parents
3-alkylindoles / Benzamides / Benzoyl derivatives / Aralkylamines / Substituted pyrroles / Piperidines / Heteroaromatic compounds / Trialkylamines / Secondary carboxylic acid amides / Amino acids and derivatives
show 5 more
Substituents
Tryptamine / 3-alkylindole / Benzamide / Benzoic acid or derivatives / Indole / Benzoyl / Aralkylamine / Monocyclic benzene moiety / Piperidine / Benzenoid
show 19 more
Molecular Framework
Aromatic heteropolycyclic compounds
External Descriptors
Not Available

Targets

Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Antagonist
General Function
Protein heterodimerization activity
Specific Function
This alpha-adrenergic receptor mediates its action by association with G proteins that activate a phosphatidylinositol-calcium second messenger system. Its effect is mediated by G(q) and G(11) prot...
Gene Name
ADRA1A
Uniprot ID
P35348
Uniprot Name
Alpha-1A adrenergic receptor
Molecular Weight
51486.005 Da
References
  1. Foglar R, Shibata K, Horie K, Hirasawa A, Tsujimoto G: Use of recombinant alpha 1-adrenoceptors to characterize subtype selectivity of drugs for the treatment of prostatic hypertrophy. Eur J Pharmacol. 1995 Jan 16;288(2):201-7. [PubMed:7536677]
  2. Forray C, Bard JA, Wetzel JM, Chiu G, Shapiro E, Tang R, Lepor H, Hartig PR, Weinshank RL, Branchek TA, et al.: The alpha 1-adrenergic receptor that mediates smooth muscle contraction in human prostate has the pharmacological properties of the cloned human alpha 1c subtype. Mol Pharmacol. 1994 Apr;45(4):703-8. [PubMed:8183249]

Drug created on May 27, 2014 13:11 / Updated on October 02, 2017 06:11